Autor/in Eggemann, H 2 Rezai, M Eidtmann, H 1 Eiermann, W 1 Fasching, P A 1 Friedrichs, K 1 Hanusch, C 1 Hilfrich, J 1 Jackisch, C 1 Kittel, K 1 Kühn, T 1 Kümmel, S 1 Loibl, S 1 Markmann, S 1 Schneeweiss, A 1 Schrader, I 1 Tesch, H 1 Untch, M 1 Warm, M 1 von Minckwitz, G 1 alle zeigenListe einklappen
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)† von Minckwitz, G Loibl, S Untch, M Eidtmann, H Rezai, M Fasching, P A Tesch, H 2014 - Forschungsinformationssystem des UKE
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Eiermann, W Rezai, M Kümmel, S Kühn, T Warm, M Friedrichs, K Schneeweiss, A 2013 - Forschungsinformationssystem des UKE
